Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Nov 12, 2021 (5 years ago)

Midazolam in 0.9% Sodium Chloride Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Midazolam in 0.9% Sodium Chloride Injection, 100 mg per 100 mL (1 mg per mL), Rx only, SterRx, 141 Idaho Ave., Plattsburgh, NY 12903, NDC 70324-102-02.

Affected NDC 70324-0102-02

Compare with the code on your package — it is the most precise check available.

Drug: Midazolam

Recalling firm
SterRx, LLC
NDC code
70324-102-02
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0312-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Midazolam recalls

See all
Class II · Moderate risk

midazolam in dextrose 5%

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Terminated Sterility / contamination Central Admixture Pharmacy Services Inc NDC 71286-4036-1 D-1075-2023
Class II · Moderate risk

Midazolam Injection

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Ongoing Stability / shelf life Akorn, Inc. D-0859-2023

Other recalls by SterRx, LLC

All 2021 recalls